Company
Business
Stem Cell Therapy
Organoid
CDMO Business
IR Resource Center
Kangstem Biotech strives to develop an innovative new drug for patients suffering from rare and incurable diseases.
Participation in BIO USA
05
2025.06
Kangstem Biotech announced that it will participate in the 2025 BIO International Convention(BIO USA), to be held in Boston, USA, from June 16 to 19.
Kangstem Biotech announced that it will participate in the 2025 BIO International Convention(BIO USA), to be held in Boston, USA, from June 16 to 19. The company plans to engage in detailed discussions on strategic collaborations regarding its knee osteoarthritis treatment candidate, OSCA, and its skin organoid technology, particularly with several top 10 global pharmaceutical companies.
Discussions around OSCA will be based on the company’s Phase 1 clinical trial data and will involve a European pharmaceutical firm specializing in orthopedics. This partner has experience conducting large-scale Phase 3 trials for new drug candidates in knee osteoarthritis and has recognized the therapeutic potential of OSCA. Impressed with its efficacy, the partner has proposed potential commercialization discussions. In addition, a U.S.-based multinational pharmaceutical company is in talks to collaborate on a development model for osteoarthritis treatments, using structural improvement data from OSCA’s Phase 1 trial, including pain indicators and radiologic assessments.
Following the U.S. FDA’s removal of mandatory animal testing requirements, global pharmaceutical companies are actively seeking partnerships with firms that possess alternative testing technologies such as organoids. Kangstem Biotech’s skin organoids not only replicate disease models for conditions such as atopic dermatitis, enabling accurate efficacy evaluation of drug candidates, but also significantly reduce time and cost compared to animal testing. Furthermore, because the organoids are derived from human cells, they offer more consistent and reliable data with closer alignment to clinical outcomes.
Leveraging this competitive edge, Kangstem has already initiated networking with three top-tier global pharmaceutical companies and a leading global cosmetics brand ahead of BIO USA. Discussions will center around potential technological collaborations based on its proprietary skin organoid platform.
The Head of Business Development at Kangstem Biotech stated, “We have over 30 meetings scheduled during the convention. Our skin organoid technology is uniquely differentiated, as it accurately mimics human skin in form, structure, and function, and has proven its potential as an experimental model. As a result, we are in active discussions with major pharmaceutical companies regarding potential technology transfer deals. Notably, because organoid technology can be licensed without the need for separate clinical trials, negotiations can proceed rapidly.”
He added, “OSCA demonstrated structural improvements such as pain relief, functional enhancement, cartilage regeneration, and subchondral bone repair in Phase 1. If these effects are confirmed in our ongoing Phase 2a trial involving over 100 patients, we are confident it could lead to a major deal.”